Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2007 1
2012 3
2013 3
2014 9
2015 8
2016 8
2017 9
2018 6
2019 13
2020 17
2021 20
2022 8
2023 3
2024 1

Text availability

Article attribute

Article type

Publication date

Search Results

96 results

Results by year

Filters applied: . Clear all
Page 1
First-line nivolumab plus ipilimumab for metastatic non-small cell lung cancer, including patients with ECOG performance status 2 and other special populations: CheckMate 817.
Ready NE, Audigier-Valette C, Goldman JW, Felip E, Ciuleanu TE, Rosario García Campelo M, Jao K, Barlesi F, Bordenave S, Rijavec E, Urban L, Aucoin JS, Zannori C, Vermaelen K, Arén Frontera O, Curioni Fontecedro A, Sánchez-Gastaldo A, Juan-Vidal O, Linardou H, Poddubskaya E, Spigel DR, Ahmed S, Maio M, Li S, Chang H, Fiore J, Acevedo A, Paz-Ares L. Ready NE, et al. Among authors: rijavec e. J Immunother Cancer. 2023 Feb;11(2):e006127. doi: 10.1136/jitc-2022-006127. J Immunother Cancer. 2023. PMID: 36725084 Free PMC article. Clinical Trial.
Safety of extended interval dosing immune checkpoint inhibitors: a multicenter cohort study.
Cantini L, Paoloni F, Pecci F, Spagnolo F, Genova C, Tanda ET, Aerts S, Rebuzzi SE, Fornarini G, Zoratto F, Fancelli S, Lupi A, Della Corte CM, Parisi A, Bennati C, Ortega C, Atzori F, Piovano PL, Orciuolo C, De Tursi M, Ghidini M, Botticelli A, Scagnoli S, Belluomini L, Leporati R, Veccia A, Di Giacomo AM, Festino L, Cortinovis D, Acquati M, Filetti M, Giusti R, Tucci M, Sergi MC, Garutti M, Puglisi F, Manglaviti S, Citarella F, Santoni M, Rijavec E, Lo Russo G, Santini D, Addeo A, Antonuzzo L, Indini A, Rocchi MBL, Cortellini A, Grossi F, Ascierto PA, Aerts JGJV, Berardi R. Cantini L, et al. Among authors: rijavec e. J Natl Cancer Inst. 2023 Jul 6;115(7):796-804. doi: 10.1093/jnci/djad061. J Natl Cancer Inst. 2023. PMID: 37042716 Free PMC article.
Metabolic disorders and the risk of cholangiocarcinoma.
Ghidini M, Ramai D, Facciorusso A, Singh J, Tai W, Rijavec E, Galassi B, Grossi F, Indini A. Ghidini M, et al. Among authors: rijavec e. Expert Rev Gastroenterol Hepatol. 2021 Sep;15(9):999-1007. doi: 10.1080/17474124.2021.1946393. Epub 2021 Aug 21. Expert Rev Gastroenterol Hepatol. 2021. PMID: 34423721 Review.
Immune checkpoint inhibitor therapy for hepatocellular carcinoma.
Ramai D, Shapiro A, Facciorusso A, Bareggi C, Gambini D, Rijavec E, Tomasello G, Galassi B, Ghidini M. Ramai D, et al. Among authors: rijavec e. Ann Gastroenterol. 2022 Nov-Dec;35(6):568-576. doi: 10.20524/aog.2022.0746. Epub 2022 Oct 3. Ann Gastroenterol. 2022. PMID: 36406972 Free PMC article. Review.
Prognostic Role of Soluble and Extracellular Vesicle-Associated PD-L1, B7-H3 and B7-H4 in Non-Small Cell Lung Cancer Patients Treated with Immune Checkpoint Inhibitors.
Genova C, Tasso R, Rosa A, Rossi G, Reverberi D, Fontana V, Marconi S, Croce M, Dal Bello MG, Dellepiane C, Tagliamento M, Ciferri MC, Zullo L, Fedeli A, Alama A, Cortese K, Gentili C, Cella E, Anselmi G, Mora M, Barletta G, Rijavec E, Grossi F, Pronzato P, Coco S. Genova C, et al. Among authors: rijavec e. Cells. 2023 Mar 8;12(6):832. doi: 10.3390/cells12060832. Cells. 2023. PMID: 36980174 Free PMC article.
Hematopoietic growth factors in lung cancer.
Genova C, Rijavec E, Grossi F. Genova C, et al. Among authors: rijavec e. Curr Opin Oncol. 2016 Mar;28(2):135-44. doi: 10.1097/CCO.0000000000000268. Curr Opin Oncol. 2016. PMID: 26742020 Review.
CIMAvax-EGF, a therapeutic non-small cell lung cancer vaccine.
Tagliamento M, Rijavec E, Barletta G, Biello F, Rossi G, Grossi F, Genova C. Tagliamento M, et al. Among authors: rijavec e. Expert Opin Biol Ther. 2018 Jul;18(7):829-835. doi: 10.1080/14712598.2018.1492539. Epub 2018 Jul 4. Expert Opin Biol Ther. 2018. PMID: 29936901 Review.
Ramucirumab: preclinical research and clinical development.
Aprile G, Rijavec E, Fontanella C, Rihawi K, Grossi F. Aprile G, et al. Among authors: rijavec e. Onco Targets Ther. 2014 Oct 29;7:1997-2006. doi: 10.2147/OTT.S61132. eCollection 2014. Onco Targets Ther. 2014. PMID: 25378934 Free PMC article. Review.
Afatinib and Erlotinib in the treatment of squamous-cell lung cancer.
Tagliamento M, Genova C, Rijavec E, Rossi G, Biello F, Dal Bello MG, Alama A, Coco S, Boccardo S, Grossi F. Tagliamento M, et al. Among authors: rijavec e. Expert Opin Pharmacother. 2018 Dec;19(18):2055-2062. doi: 10.1080/14656566.2018.1540591. Epub 2018 Nov 3. Expert Opin Pharmacother. 2018. PMID: 30392436 Review.
96 results